Hakutulokset - Jan Müller‐Brand

  • Näytetään 1 - 14 yhteensä 14 tuloksesta
Tarkenna hakua
  1. 1
    Plasma potassium in patients with terminal renal failure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium

    Plasma potassium in patients with terminal renal failure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium Tekijä A Blumberg, H.W. Roser, C Zehnder, Jan Müller‐Brand

    Julkaistu 1997
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease

    The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease Tekijä Martin A. Walter, R Melzer, Christian Schindler, Jan Müller‐Brand, Alan Tyndall, Egbert Nitzsche

    Julkaistu 2005
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study

    The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study Tekijä Martin A. Walter, Christian P. Turtschi, Christian Schindler, Peter Minnig, Jan Müller‐Brand, Beat P. Müller‐Stich

    Julkaistu 2007
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study

    In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study Tekijä Flavio Forrer, Jianhua Chen, Melpomeni Fani, P. Powell, Andreas Lohri, Jan Müller‐Brand, Gerhard Moldenhauer, Helmut R. Maëcke

    Julkaistu 2009
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    Somatostatin Receptor–Targeted Radiopeptide Therapy with <sup>90</sup>Y-DOTATOC and <sup>177</sup>Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial

    Somatostatin Receptor–Targeted Radiopeptide Therapy with <sup>90</sup>Y-DOTATOC and <sup>177</sup>Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Tri... Tekijä Nicolas Marincek, Piotr Radojewski, Rebecca A. Dumont, Philippe Brunner, Jan Müller‐Brand, Helmut R. Maëcke, Matthias Briel, Martin A. Walter

    Julkaistu 2015
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial

    Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial Tekijä Dominik Cordier, Flavio Forrer, Frank Bruchertseifer, Alfred Morgenstern, Christos Apostolidis, Stephan Good, Jan Müller‐Brand, Helmut R. Mäcke, J.C. Reubi, Adrian Merlo

    Julkaistu 2010
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials

    Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials Tekijä Martin A. Walter, Matthias Briel, Mirjam Christ‐Crain, Steen Joop Bonnema, John Connell, David S. Cooper, Heiner C. Bucher, Jan Müller‐Brand, Beat P. Müller‐Stich

    Julkaistu 2007
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  8. 8
    Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours

    Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours Tekijä Anna Romer, Daniela Seiler, Nicolas Marincek, Philippe Brunner, Michael Koller, Quinn K.T. Ng, Helmut R. Maëcke, Jan Müller‐Brand, Christoph Rochlitz, Matthias Briel, Christian Schindler, Martin A. Walter

    Julkaistu 2013
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  9. 9
    Cohort Study of Somatostatin-Based Radiopeptide Therapy With [<sup>90</sup>Y-DOTA]-TOC Versus [<sup>90</sup>Y-DOTA]-TOC Plus [<sup>177</sup>Lu-DOTA]-TOC in Neuroendocrine Cancers

    Cohort Study of Somatostatin-Based Radiopeptide Therapy With [<sup>90</sup>Y-DOTA]-TOC Versus [<sup>90</sup>Y-DOTA]-TOC Plus [<sup>177</sup>Lu-DOTA]-TOC in Neuroendocrine Cancers Tekijä Linda Villard, Anna Romer, Nicolas Marincek, Philippe Brunner, Michael Koller, Christian Schindler, Quinn K.T. Ng, Helmut R. Mäcke, Jan Müller‐Brand, Christoph Rochlitz, Matthias Briel, Martin A. Walter

    Julkaistu 2012
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  10. 10
    Progression to Overt or Silent CAD in Asymptomatic Patients With Diabetes Mellitus at High Coronary Risk

    Progression to Overt or Silent CAD in Asymptomatic Patients With Diabetes Mellitus at High Coronary Risk Tekijä Michael J. Zellweger, Michael Maraun, Hans H. Osterhues, Ulrich Keller, Jan Müller‐Brand, Raban Jeger, Otmar Pfister, Thilo Burkard, Friedrich Eckstein, Stefanie von Felten, Stefan Osswald, Matthias Pfisterer

    Julkaistu 2014
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  11. 11
    Procalcitonin levels predict clinical course and progression‐free survival in patients with medullary thyroid cancer

    Procalcitonin levels predict clinical course and progression‐free survival in patients with medullary thyroid cancer Tekijä Martin A. Walter, Christian Meier, Tanja Radimerski, Fabienne Iten, Marius Kränzlin, Jan Müller‐Brand, Jan Willem B. de Groot, Ido P. Kema, Thera P. Links, Beat P. Müller‐Stich

    Julkaistu 2009
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  12. 12
    Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors

    Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors Tekijä Nancy Sharma, Boris G. Naraev, Eric G. Engelman, M. Bridget Zimmerman, David Bushnell, Thomas M. O’Dorisio, M. Sue O’Dorisio, Yusuf Menda, Jan Müller‐Brand, James R. Howe, Þorvarður R. Hálfdánarson

    Julkaistu 2016
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  13. 13
    The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors

    The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors Tekijä Philippe Brunner, Ann-Catherine Jörg, Katharina Glatz, Lukas Bubendorf, Piotr Radojewski, M Umlauft, Nicolas Marincek, Petar-Marko Spanjol, Thomas Krause, Rebecca A. Dumont, Helmut R. Maëcke, Jan Müller‐Brand, Matthias Briel, Anja Schmitt, Aurel Perren, Martin A. Walter

    Julkaistu 2016
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  14. 14
    The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis

    The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis Tekijä Martin Fuchs, Matthias Briel, Thomas Daikeler, Ulrich A. Walker, Helmut Rasch, Scott Berg, Quinn K.T. Ng, Heike Raatz, David Jayne, Ina Kötter, Daniël Blockmans, María C. Cid, Sergio Prieto‐González, Peter Lamprecht, Carlo Salvarani, Zaharenia Th. Karageorgaki, Richard A. Watts, Raashid Luqmani, Jan Müller‐Brand, Alan Tyndall, Martin A. Walter

    Julkaistu 2011
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: